Compositions and methods for detecting allogeneic matter in a subject

Patent metadata

Field	Value
Publication number	US-2020181702-A1
Application number	US-202016795375-A
Country	US
Kind code	A1
Filing date	Feb 19, 2020
Priority date	Mar 1, 2012
Publication date	Jun 11, 2020
Grant date	—

Abstract

The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

First claim

What is claimed is:

1 . A process for detecting microchimerism, comprising:
(a) amplifying nucleic acid molecules of a target biological sample using one or more specific nucleic acid molecule compositions comprising a forward nucleic acid molecule, a reverse nucleic acid molecule, and a probe nucleic acid molecule; (b) amplifying nucleic acid molecules of a control biological sample using the one or more specific nucleic acid molecule compositions of step (a); (c) comparing the amount of amplified nucleic acid molecules with a reference to quantitate the specific nucleic acid molecule markers in the samples; wherein each specific nucleic acid molecule composition amplifies a particular genetic polymorphism; and wherein the presence of certain specific amplified markers in the target biological sample indicates the presence of microchimerism.

2 . The process of claim 1 , wherein:
(i) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 1, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 2, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 3; (ii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 4, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 5, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 6; (iii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 7, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 8, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 9; (iv) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 10, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 11, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 12; (v) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 13, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 14, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 15; (vi) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 16, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 17, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 18; (vi) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 19, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 20, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 21; (vii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 22, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 23, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 24; (viii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 25, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 26, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 27; (ix) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 67, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 68, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 69; (x) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 31, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 32, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 33; (xi) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 34, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 35, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 36; (xii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 37, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 38, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 39; (xiii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 40, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 41, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 42; (xiv) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 43, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 44, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 45; (xv) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 46, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 47, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 48; (xvi) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 49, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 50, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 51; (xvii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 52, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 53, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 54; (xviii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 55, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 56, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 57; (xix) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 58, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 59, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 60; (xx) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 61, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 62, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 63; (xxi) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 64, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO:65, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 66; (xxii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 70, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 71, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 72; (xxiii) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 73, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 74, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 75; (xxiv) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 76, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 77, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 78; (xxv) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 79, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 80, and the probe nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 81; or (xxvi) the forward nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 82, the reverse nucleic acid molecule comprises the sequence set forth in SEQ ID NO: 83, a

Assignees

• Hutchinson Fred Cancer Res

Inventors

• Nelson J Lee
• Lambert Nathalie C
• Gadi Vijayakrishna K
• Yan Zhen

Classifications

• C12Q1/6881 Primary

  for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/158

  Expression markers · CPC title